TISSUE REGENIX GROUP PLC - ORD 0.1P
TISSUE REGENIX GROUP PLC - ORD 0.1P
Aktie · GB00B5SGVL29 (XLON)
Übersicht Finanzkennzahlen
0,32 GBP
0,63 % 0,002 GBP
Schlusskurs XLON 06.06.2025: 31,70 GBX
London (XLON) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 14:49

Aktuelle Kurse von TISSUE REGENIX GROUP PLC - ORD 0.1P

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XLON: London
London
TRX.L
GBX
06.06.2025 14:49
31,70 GBX
31,10 GBX
+1,93 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % -0,94 % -3,94 % -23,06 % -44,39 % -53,72 % -14,32 %

Firmenprofil zu TISSUE REGENIX GROUP PLC - ORD 0.1P Aktie

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.

Unternehmensdaten

Name TISSUE REGENIX GROUP PLC - ORD 0.1P
Firma Tissue Regenix Group plc
Website https://www.tissueregenix.com
Heimatbörse XLON London
ISIN GB00B5SGVL29
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Daniel Ray Lee
Marktkapitalisierung 26 Mio
Land Großbritannien und Nordirland
Währung GBP
Mitarbeiter 0,1 T
Adresse Unit 3, LS25 2GY Garforth
IPO Datum 2006-12-21

Aktien-Splits

Datum Split
28.04.2023 1:100
29.06.2010 1:5

Ticker Symbole

Name Symbol
London TRX.L

Weitere Aktien

Investoren die TISSUE REGENIX GROUP PLC - ORD 0.1P die halten, haben auch folgende Aktien im Depot:
BAYER US FIN 23/29 REGS
BAYER US FIN 23/29 REGS Anleihe
INVESTEC PLC
INVESTEC PLC Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025